Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research
BALA CYNWYD, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich's ataxia will be featured in three presentations at the upcoming . The conference will take place November 1 – 4, 2022, in Dallas, Texas.
Details on the presentations are shown below.
| Title: | Safety and Pharmacokinetics of Single and 13 Day Multiple-Dose Administration of CTI-1601, a Frataxin Replacement Therapy for Friedreich’s Ataxia | |
| Presentation Format: | Oral | |
| Presenting Author: | Nancy M. Ruiz, MD, Chief Medical Officer, Larimar Therapeutics | |
| Presentation Date and Time: | November 3, 2022, at 4:00 PM CT |
| Title: | Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia | |
| Presentation Format: | Poster | |
| Presenting Author: | David Bettoun, PhD, Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics | |
| Poster Session Date and Time: | 12:00 -1:00 PM CT on November 2 and 3, 2022 |
| Title: | Identification of Differentially Expressed Genes in Friedreich’s Ataxia Patients | |
| Presentation Format: | Poster | |
| Presenting Author: | Matthew Baile, PhD, Senior Research Investigator, Larimar Therapeutics | |
| Poster Session Date and Time: | 12:00 -1:00 PM CT on November 2 and 3, 2022 |
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: .
Investor Contact:
Joyce Allaire
LifeSci Advisors
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
(484) 414-2715
